House dust mite allergy immunotherapy - ASIT Biotech

Drug Profile

House dust mite allergy immunotherapy - ASIT Biotech

Alternative Names: hdm-ASIT+

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator ASIT biotech
  • Class Allergy immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Rhinoconjunctivitis

Most Recent Events

  • 30 Nov 2016 ASIT biotech completes enrolment in its phase IIa trial for Rhinoconjunctivitis in Germany
  • 22 Sep 2016 Paul Ehrlich Institut and the Ethic Committee of the Technical University Dresden approves a phase IIa trial in Rhinoconjunctivitis in Germany
  • 22 Sep 2016 Phase-II clinical trials in Rhinoconjunctivitis in Germany (SC) (EudraCT2016-000557-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top